Drug Price Trends for EPLERENONE

Average Pharmacy Cost for EPLERENONE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EPLERENONE 25 MG TABLET	16571-0173-09	0.36124	EACH	2025-12-17
EPLERENONE 25 MG TABLET	16729-0293-10	0.36124	EACH	2025-12-17
EPLERENONE 25 MG TABLET	31722-0049-90	0.36124	EACH	2025-12-17
EPLERENONE 25 MG TABLET	16571-0173-03	0.36124	EACH	2025-12-17
EPLERENONE 25 MG TABLET	16729-0293-15	0.36124	EACH	2025-12-17
EPLERENONE 50 MG TABLET	69367-0308-30	0.49674	EACH	2025-12-17

Best Wholesale Price for EPLERENONE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
EPLERENONE 25MG TAB	AvKare, LLC	69367-0307-09	90	43.04	0.47822	EACH	2023-06-15 - 2028-06-14	FSS
EPLERENONE 25MG TAB	AvKare, LLC	69367-0307-30	30	10.24	0.34133	EACH	2023-06-15 - 2028-06-14	FSS
EPLERENONE 25MG TAB	AvKare, LLC	42291-0454-30	30	9.73	0.32433	EACH	2024-01-12 - 2028-06-14	FSS
EPLERENONE 50MG TAB	AvKare, LLC	69367-0308-09	90	69.56	0.77289	EACH	2023-06-15 - 2028-06-14	FSS
EPLERENONE 25MG TAB	AvKare, LLC	42291-0454-90	90	30.32	0.33689	EACH	2023-06-15 - 2028-06-14	FSS
EPLERENONE 50MG TAB	AvKare, LLC	69367-0308-30	30	14.34	0.47800	EACH	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for Eplerenone

Last updated: July 27, 2025

---

Introduction

Eplerenone, marketed primarily under the brand name Inspra, is a selective aldosterone receptor antagonist developed by Pfizer. Approved by the U.S. Food and Drug Administration (FDA) in 2007, it is primarily prescribed for conditions such as heart failure with reduced ejection fraction (HFrEF) and hypertension, especially in patients with type 2 diabetes and existing cardiovascular risk factors. As its patent protections extend and generic formulations emerge, understanding the market dynamics and price projections for eplerenone becomes critical for stakeholders, including pharmaceutical companies, investors, healthcare providers, and policymakers.

---

Pharmacological Profile and Market Positioning

Eplerenone distinguishes itself from spironolactone, its predecessor, through higher selectivity for mineralocorticoid receptors, thus reducing side effects like gynecomastia. Its efficacy in managing post-myocardial infarction heart failure and resistant hypertension positions it as a vital therapy for specific patient populations.

Currently, the drug is indicated for:

• Heart failure with reduced ejection fraction (HFrEF)
• Hypertension in patients at risk of hyperkalemia or endocrine adverse effects

Despite its clinical utility, eplerenone's market share is comparatively smaller than spironolactone due to factors like cost and brand recognition, but its safety profile supports potential growth in targeted